Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria

BACKGROUND: Lenvatinib is one of the first-line treatments for unresectable hepatocellular carcinoma (HCC). However, data are lacking on lenvatinib in the postoperative setting. METHODS: This retrospective analysis enrolled 242 patients with HCC who underwent liver transplantation (LTx). Eligible pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, De-Zhen, Cheng, Jian-Wen, Yan, Jia-Yan, Huang, Ao, Wang, Yu-Peng, Zhang, Shi-Yu, Cao, Ya, Huang, Xiao-Wu, Fan, Jia, Zhou, Jian, Yang, Xin-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652551/
https://www.ncbi.nlm.nih.gov/pubmed/36388794
http://dx.doi.org/10.21037/atm-22-1353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652551/
https://www.ncbi.nlm.nih.gov/pubmed/36388794
http://dx.doi.org/10.21037/atm-22-1353

Ejemplares similares